Novo Nordisk’s GLP-1 pill has reignited the competition in the GLP-1 space.
But you can sidestep that drama by buying this surgical robotics pioneer.
Drugmakers Novo Nordisk and Eli Lilly are battling it out in the GLP-1 weight loss market. The pill version of Novo Nordisk’s Ozempic has reignited competition between theses two fierce rivals.
Meanwhile, another major presence in the medical world — device maker Intuitive Surgical (NASDAQ: ISRG) — continues to chug along. And it looks set to do so regardless of which drug company wins the GLP-1 race.
Will AI create the world’s first trillionaire? Our team just released a report on the one little-known company, called an “Indispensable Monopoly” providing the critical technology Nvidia and Intel both need. Continue »
Here’s why you might want to add Intuitive Surgical shares to your investment portfolio.
The truth is that GLP-1 weight loss drugs are an exciting development. So it is reasonable that Wall Street is heavily focused on the pharmaceutical companies leading the charge. However, there is a lot more going on in the healthcare sector. One still exciting niche is surgical robotics, where Intuitive Surgical was a pioneer thanks to its da Vinci robot.
Image source: Getty Images.
At the end of 2025, Intuitive Surgical had 11,106 of its surgical robots in the market, up 12% from 9,902 at the end of 2024. Meanwhile, the number of surgeries performed with a da Vinci system rose 18% year over year. There is clearly material demand among practitioners and patients for robotic surgery. That makes sense, given the generally less invasive nature of the process and often improved surgical outcomes.
That said, Wall Street isn’t really ignoring Intuitive Surgical. The medical device maker’s price-to-earnings ratio is very high at 61. However, that’s actually below the five-year average P/E ratio of 71. So, historically speaking, the stock looks relatively cheap even if it looks expensive on an absolute level.
Longer-term, the opportunity remains quite compelling for aggressive growth investors. With more and more surgeries performed using surgical robots, it seems likely that demand for da Vinci systems will remain strong. Meanwhile, there’s an artificial intelligence (AI) angle, with the company already incorporating the technology to assist surgeons.
That said, it seems highly likely that AI could someday use surgical robots like the da Vinci system to perform surgeries. Given the da Vinci system’s installed base, it could be a prime beneficiary of such an advance.
Intuitive Surgical is a growth stock, and anyone with a value bias should look elsewhere. However, if you are a growth investor in the healthcare sector, you might want to set aside GLP-1 makers for a moment and consider this high-flying medical device company. It has material opportunities ahead, and the stock could be viewed as cheap relative to its historical valuation.
Before you buy stock in Intuitive Surgical, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Intuitive Surgical wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $415,256!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,151,865!*
Now, it’s worth noting Stock Advisor’s total average return is 892% — a market-crushing outperformance compared to 194% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of February 20, 2026.
Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Intuitive Surgical. The Motley Fool recommends Novo Nordisk and recommends the following options: long January 2028 $520 calls on Intuitive Surgical and short January 2028 $530 calls on Intuitive Surgical. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
